期刊文献+
共找到549篇文章
< 1 2 28 >
每页显示 20 50 100
Application of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) for the prevention of neutropenia in triple negative breast cancer patients older than 65 years during adjuvant chemotherapy 被引量:3
1
作者 Shuxian Qu Jianing Qiu +2 位作者 Yidan Zhang Yongming Liu Zhendong Zheng 《Oncology and Translational Medicine》 2019年第5期218-222,共5页
Objective The aim of this study was to compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)and recombinant human granulocyte colonystimulating factor(rhG-CS... Objective The aim of this study was to compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)and recombinant human granulocyte colonystimulating factor(rhG-CSF)for the prevention of neutropenia in elderly breast cancer patients during adjuvant chemotherapy.Methods A total of 45 oncology inpatients with breast cancer,who received adjuvant chemotherapy and were older than 65 years from May 2017 to October 2018 in the General Hospital of the Northern Theater of the Chinese people’s Liberation Army,were included.Epirubivin Cyclophoshamide-Docetaxel(EC-T)sequential adjuvant chemotherapy was chosen.Forty-five patients were randomly divided into two groups;25 patients in the treatment group were treated with PEG-rhG-CSF and 20 patients in the control group were not treated with PEG-rhG-CSF,but only rhG-CSF.The experimental group was treated with the PEG-rhG-CSF at the end of chemotherapy for 24–48 h,with a 6 mg subcutaneous injection once per chemotherapy cycle.In the control group,rhG-CSF was administered after 48 h of chemotherapy,with a 100μg subcutaneous injection,1/d,d 1–7.The dosage could be increased step by step with the exacerbation of neutropenia.The primary aims of this study was to discover the incidence of leukopenia,neutropenia,neutrophilic fever,and adverse reactions in the two groups.Results The incidence of neutropenia,neutrophilic fever and adverse reactions decreased in the treatment group compared to the control group,but no significant difference existed between two groups(P>0.05).Patients in treatment group had a lower,but not statistically significant,incidence of adverse reactions(P>0.05).Conclusion Applying PEG-rhG-CSF could be effective in preventing neutropenia in elderly patients with postoperative adjuvant chemotherapy to treat breast cancer.It may effectively control the occurrence of neutropenia after chemotherapy and reduce the chance of infection.The incidence of side effects,such as fever and bone pain,was low.The adverse drug reactions were well tolerated by patients,which could ensure the smooth progress of chemotherapy. 展开更多
关键词 ELDERLY BREAST cancer NEUTROPENIA pegylated recombinant human granulocyte colonystimulating factor
下载PDF
Pharmacokinetic Study of a Novel Recombinant Human Granulocyte Colony-stimulating Factor in Rats 被引量:4
2
作者 Xiao-xiao Liu Yong-ping Jiang 《Chinese Medical Sciences Journal》 CAS CSCD 2010年第1期13-19,共7页
Objective To study the pharmacokinetics of a novel recombinant human granulocyte colonystimulating factor (rhG-CSFa) in rats and to determine the proteolytic rates of rhG-CSFa in the whole blood and serum of rats in v... Objective To study the pharmacokinetics of a novel recombinant human granulocyte colonystimulating factor (rhG-CSFa) in rats and to determine the proteolytic rates of rhG-CSFa in the whole blood and serum of rats in vitro. Methods The pharmacokinetics of rhG-CSFa and conventional (wild type,WT) granulocyte colonystimulating factor (G-CSF) were investigated in Sprague-Dawley rats which received either intravenous or subcutaneous injection of rhG-CSFa or WT G-CSF at three different doses (20,50,or 100 μg/kg). The blood samples of rats were collected at multiple time points (from 0.08 to 12 h) and the concentrations of rhG-CSFa and WT G-CSF in serum were determined with a sandwich enzyme-linked immunosorbent assay (ELISA). For the study of proteolytic rates in vitro,the concentrations of rhG-CSFa or WT G-CSF were determined at 3-minute intervals after addition of the respective drug to rat’s whole blood or serum. Results Pharmacokinetic analysis of serum rhG-CSFa or WT G-CSF levels indicated that,at each dose tested,for either route of drug administration,the area under concentration-time curve values and the maximum serum concentration of rhG-CSFa were higher than those of WT G-CSF,and the serum half life of rhG-CSFa was longer than that of WT G-CSF. Subsequent in vitro whole blood and serum stability study showed that the rates of drug degradation in WT G-CSF were 1.8 folds and 1.5 folds higher than those in rhG-CSFa,respectively. Conclusion rhG-CSFa has better serum and whole blood stability in vitro and higher bioavailability in vivo as compared to WT G-CSF. 展开更多
关键词 recombinant human granulocyte colony-stimulating factor PHARMACOKINETICS half life BIOAVAILABILITY proteolytic rate
下载PDF
Refolding with Simultaneous Purification of Recombinant Human Granulocyte Colony-stimulating Factor from Escherichia coli Using Strong Anion Exchange Chromatography
3
作者 ChaoZhanWANG JiangFengLIU XinDuGENG 《Chinese Chemical Letters》 SCIE CAS CSCD 2005年第3期389-392,共4页
The urea denatured recombinant human granulocyte colony-stimulating factor (rhG- CSF) which was expressed in Escheriachia coli (E. coli) was refolded with simultaneous purification by strong anion exchange chromatogra... The urea denatured recombinant human granulocyte colony-stimulating factor (rhG- CSF) which was expressed in Escheriachia coli (E. coli) was refolded with simultaneous purification by strong anion exchange chromatography (SAX) in the presence of low concentration- of urea. The effect of urea concentration on this refolding process was investigated. The obtained refolded rhG-CSF has a high specific activity of 2.3×108 U/mg, demonstrating that the proteins were completely refolded during the chromatographic process. With only one step by SAX in 40 min, purity and mass recovery of the refolded and purified rhG-CSF were 97% and 43%, respectively. 展开更多
关键词 recombinant human granulocyte colony-stimulating factor inclusion bodies protein refolding PURIFICATION strong anion exchange chromatography.
下载PDF
Anti-apoptotic effects of recombinant human granulocyte colony-stimulating factor in focal cerebral ischemic rats
4
作者 Xia Yuan Shiming Zhang +1 位作者 Wanli Dong Qi Fang 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第11期839-844,共6页
The neuroprotective effects of granulocyte colony-stimulating factor in cerebral ischemia/reperfusion injury are currently contentious. The present study examined the effects of subcutaneous injection of recombinant h... The neuroprotective effects of granulocyte colony-stimulating factor in cerebral ischemia/reperfusion injury are currently contentious. The present study examined the effects of subcutaneous injection of recombinant human granulocyte colony-stimulating factor (50 pg/kg) over 5 days in a model of cerebral ischemia/reperfusion with intraluminal filament occlusion in rats. The results indicated that recombinant human granulocyte colony-stimulating factor reduced brain infarct volume following cerebral ischemia/reperfusion injury in rats, down-regulated the expression of caspase-3 mRNA (a key protease for apoptosis in the cerebral ischemia zone), lowered the rate of neuronal apoptosis in the cerebral ischemia zone, and notably ameliorated neurological function. These results indicate that recombinant human granulocyte colony-stimulating factor has anti-apoptotic effects on neurons following focal cerebral ischemia/reperfusion injury, and exerts neuroprotective effects. 展开更多
关键词 recombinant human granulocyte colony-stimulating factor cerebral ischemia/ reperfusion injury ANTI-APOPTOSIS neural regeneration
下载PDF
A New Protocol for Solubilization, Refolding and Purification of Recombinant Human Granulocyte Colony-stimulating Factor in Inclusion Bodies
5
作者 Jia Hua LIU Chao Zhan WANG Xin Du GENG 《Chinese Chemical Letters》 SCIE CAS CSCD 2006年第6期799-802,共4页
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) in inclusion bodies was solubilized by 8 mol/L urea solution and subsequently precipitated by acetone to improve its purity. After that, the precipit... Recombinant human granulocyte colony-stimulating factor (rhG-CSF) in inclusion bodies was solubilized by 8 mol/L urea solution and subsequently precipitated by acetone to improve its purity. After that, the precipitates were solubilized by sodium hydroxide solution containing 2 mol/L urea. Then the solubilized rhG-CSF was passed through a size exclusion chromatography for refolding and extensive purification, and further purified by a weak anion exchange chromatography. The purity and mass recovery of refolded rhG-CSF were 96.5% and 75.6%, respectively. The bioactivity was 8.4x10^7 IU/mg. 展开更多
关键词 recombinant human granulocyte colony-stimulating factor alkaline solution solubilization of inclusion bodies protein refolding.
下载PDF
CONSTRUCTION OF EUKARYOTIC EXPRESSION VECTOR WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE 被引量:4
6
作者 郑秋红 郑天荣 +2 位作者 谢云青 卢林 陈晖 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2000年第2期125-127,共3页
Objective: To construct the eukaryotic expression vector that express human granulocyte-macrophage colony-stimulating factor (hGM-CSF) gene for making highly express in mammalian cells. Methods: Extract totally RNA fr... Objective: To construct the eukaryotic expression vector that express human granulocyte-macrophage colony-stimulating factor (hGM-CSF) gene for making highly express in mammalian cells. Methods: Extract totally RNA from the induced human fetal lung (HFL) cell line. HGM-CSF cDNA was obtained by reverse transcription-polymerase chain reaction (RT-PCR), and then directionally subcloned into the HindIII and EcoRI site on the pcDNA3.1 plasmid, which was controlled by the CMV promoter, to form the recombinant expressing vector pcDNA3.1-GM-CSF. Results: The PCR amplification was identified and the sequence was analyzed, the results showed that hGM-CSF was properly inserted into the vector and the sequence was correct. 展开更多
关键词 human granulocyte-macrophage colony-stimulating factor (hGM-CSF) Reverse transcription and polymerse chain reaction (RT-PCR) Eukaryotic expression
下载PDF
Pharmacokinetics of recombinant human granulocyte macrophage colony-stimulating factor in Macaca mulata 被引量:7
7
作者 王仁刚 朱兴族 宋伟 《中国药理学报》 CSCD 1998年第1期50-53,共4页
目的:研究重组人粒细胞巨噬细胞集落刺激因子(rhGMCSF)在恒河猴体内的药物动力学.方法:用酶连接免疫吸附测定法检测血浆中rhGMCSF的含量.结果:ivrhGMCSF后血药浓度时间曲线符合三房室模型.第1,... 目的:研究重组人粒细胞巨噬细胞集落刺激因子(rhGMCSF)在恒河猴体内的药物动力学.方法:用酶连接免疫吸附测定法检测血浆中rhGMCSF的含量.结果:ivrhGMCSF后血药浓度时间曲线符合三房室模型.第1,2和3相的T12分别为005-007h,014-058h和14-41h.AUC随剂量成比例增加.iv高剂量和低剂量的Cl和K10都相似.scrhGMCSF后血药浓度的峰值为093±016μg·L-1,达峰时间为265±014h,生物利用度为061.结论:恒河猴rhGMCSF药物动力学数据为临床试验提供有用参考. 展开更多
关键词 ELISA RHGM-CSF
原文传递
Clinical Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Leukopenia.
8
《Chinese Medical Journal》 SCIE CAS CSCD 1995年第1期47-47,共1页
We have studied the efficacy and safery of recombinant human granulocyte-macrophate colony-stimulating factor
关键词 CSF Clinical Study of recombinant human granulocyte-macrophage colony-stimulating factor on Chemotherapy-Induced Leukopenia cycle
原文传递
A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma 被引量:2
9
作者 Xin Dong Wei Deng +6 位作者 Leilei Jiang Dan Yang Huiming Yu Dongming Li Anhui Shi Rong Yu Weihu Wang 《Radiation Medicine and Protection》 2022年第2期81-85,共5页
Objective:To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)for preventive or delayed treatment in neutropenia,completion rate of concurrent chemoradio... Objective:To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)for preventive or delayed treatment in neutropenia,completion rate of concurrent chemoradiotherapy and hospitalization rate in patients with esophageal squamous carcinoma during definitive concurrent chemoradiotherapy.Methods:A total of 70 patients with esophageal squamous carcinoma in Peking University Cancer Hospital from January 2019 to December 2020,who received PEG-rhG-CSF during concurrent chemoradiotherapy,were enrolled in this retrospective analysis.There were 32 patients in the preventive group,and 38 patients in the delayed group.The incidence of neutropenia,completion rate of concurrent chemoradiotherapy and neutropeniarelated hospitalization rate were compared between PEG-rhG-CSF preventive group and delayed group.Results:The incidence of severe neutropenia(Grades 3–4)in all patients was 31.4%.Comparison between preventive group and delayed group showed that the incidence of severe neutropenia was 6.3%and 39.4%(χ^(2)=10.428,P=0.001),respectively.In preventive group,the incidence of severe neutropenia was 3.7%and 20.0%,respectively,for primary prevention and secondary prevention of PEG-rhG-CSF(χ^(2)=12.321,P=0.001).The completion rate of concurrent chemoradiotherapy was 93.8%in the preventive group and 63.2%in the delayed group(χ^(2)=9.220,P=0.002).The incidence of treatment interruption was 25.7%in the whole group,12.5%in the preventive group and 36.8%in the delayed group(χ^(2)=5.389,P=0.020).Seven patients(7/70,10.0%)were hospitalized and treated with intravenous antibiotics for neutropenia,including 1 in the preventive group and 6 in the delayed group(P=0.078).Conclusions:Prophylactic use of PEG-rhG-CSF during concurrent chemoradiotherapy for patients with esophageal squamous carcinoma can effectively reduce the incidence of neutropenia,ensure the safety of treatment,and improve the completion rate of concurrent chemoradiotherapy. 展开更多
关键词 Esophageal squamous carcinoma Concurrent chemoradiotherapy Pegylated recombinant human granulocyte colony-stimulating factor
原文传递
APPLICATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION
10
作者 DPLu NLGuo +4 位作者 XJHuang JZhang YMFan QShi BJiang 《Chinese Medical Journal》 SCIE CAS CSCD 1994年第10期19-20,共2页
The effect of rhG-CSF (Filgrastim by Amgen Co.as Neupogen and Kirin Co.as Gran) was evaluated in 20 patients with leukemia after allogeneic
关键词 BMT APPLICATION OF recombinant human granulocyte colony-stimulating factor FILGRASTIM
原文传递
Bioactive materials from berberine-treated human bone marrow mesenchymal stem cells promote alveolar bone regeneration by regulating macrophage polarization
11
作者 Ziyue Qin Yanxing Han +13 位作者 Yifei Du Yixuan Zhang Yifeng Bian Ruyu Wang Haoran Wang Fanyi Guo Hua Yuan Yongchu Pan Jianliang Jin Qigang Zhou Yuli Wang Feng Han Yan Xu Jiandong Jiang 《Science China(Life Sciences)》 SCIE CAS CSCD 2024年第5期1010-1026,共17页
Alveolar bone regeneration has been strongly linked to macrophage polarization.M1 macrophages aggravate alveolar bone loss,whereas M2 macrophages reverse this process.Berberine(BBR),a natural alkaloid isolated and ref... Alveolar bone regeneration has been strongly linked to macrophage polarization.M1 macrophages aggravate alveolar bone loss,whereas M2 macrophages reverse this process.Berberine(BBR),a natural alkaloid isolated and refined from Chinese medicinal plants,has shown therapeutic effects in treating metabolic disorders.In this study,we first discovered that culture supernatant(CS)collected from BBR-treated human bone marrow mesenchymal stem cells(HBMSCs)ameliorated periodontal alveolar bone loss.CS from the BBR-treated HBMSCs contained bioactive materials that suppressed the M1 polarization and induced the M2 polarization of macrophages in vivo and in vitro.To clarify the underlying mechanism,the bioactive materials were applied to different animal models.We discovered macrophage colony-stimulating factor(M-CSF),which regulates macrophage polarization and promotes bone formation,a key macromolecule in the CS.Injection of pure M-CSF attenuated experimental periodontal alveolar bone loss in rats.Colony-stimulating factor 1 receptor(CSF1R)inhibitor or anti-human M-CSF(M-CSF neutralizing antibody,Nab)abolished the therapeutic effects of the CS of BBR-treated HBMSCs.Moreover,AKT phosphorylation in macrophages was activated by the CS,and the AKT activator reversed the negative effect of the CSF1R inhibitor or Nab.These results suggest that the CS of BBR-treated HBMSCs modulates macrophage polarization via the M-CSF/AKT axis.Further studies also showed that CS of BBR-treated HBMSCs accelerated bone formation and M2 polarization in rat teeth extraction sockets.Overall,our findings established an essential role of BBR-treated HBMSCs CS and this might be the first report to show that the products of BBR-treated HBMSCs have active effects on alveolar bone regeneration. 展开更多
关键词 BERBERINE human bone marrow mesenchymal stem cells alveolar bone regeneration macrophage colony-stimulating factor AKT phosphorylation
原文传递
儿童神经母细胞瘤化疗后严重感染的影响因素及重组人粒细胞刺激因子预防的应用效果
12
作者 杨兰 高林林 雷婉婷 《黑龙江医学》 2024年第1期24-26,共3页
目的:分析并探究儿童神经母细胞瘤(NB)化疗后严重感染的影响因素及重组人粒细胞刺激因子(rhG-CSF)预防的应用效果,为临床提供依据。方法:回顾性分析2020年3月—2021年12月南阳市中心医院收治的100例NB患儿的一般资料,统计所有患儿在化... 目的:分析并探究儿童神经母细胞瘤(NB)化疗后严重感染的影响因素及重组人粒细胞刺激因子(rhG-CSF)预防的应用效果,为临床提供依据。方法:回顾性分析2020年3月—2021年12月南阳市中心医院收治的100例NB患儿的一般资料,统计所有患儿在化疗治疗后严重感染的发生率,并统计临床上可能诱发感染的影响因素。将停止化疗24 h后立即接受rhG-CSF预防干预的患儿为观察组(n=57);将出现粒细胞缺乏现象后再接受rhG-CSF预防干预的患儿为对照组(n=43)。观察两组患者严重感染发生情况并分析其影响因素,比较rhG-CSF预防的应用效果。结果:100例患儿中严重感染发生率为27.00%(27/100)。NB患儿化疗后严重感染发生率单因素分析结果显示,不同患儿年龄、病情分期、远处转移、血清神经元特异性烯醇化酶(NSE)、手术切除、化疗药物、化疗持续时间等都会影响到患儿化疗后严重感染发生率,差异有统计学意义(χ2=5.372、6.222、6.322、5.983、4.785、10.079、7.193,P<0.05)。应用rhG-CSF干预治疗后,对照组严重感染发生率高于观察组,持续时间长于对照组,差异有统计学意义(χ^(2)=6.515;t=10.218,P<0.05)。结论:影响儿童NB化疗后严重感染的主要因素为患儿年龄、临床分期、血清NSE水平、选用的化疗药物、化疗的持续时间等,若能够在患儿化疗24 h后及时给予rhG-CSF干预治疗,则能显著降低患儿群体出现严重感染的概率,有利于更好地改善患儿的预后。 展开更多
关键词
下载PDF
超声清创术+外用重组人粒细胞巨细胞刺激因子凝胶剂对糖尿病足WagnerⅡ、Ⅲ级溃疡治疗效果及愈合情况分析
13
作者 恽瑞元 严磊 刘琳 《糖尿病新世界》 2024年第7期179-182,共4页
目的探究超声清创术+外用重组人粒细胞巨细胞刺激因子凝胶剂在糖尿病足WagnerⅡ、Ⅲ级溃疡治疗中的应用效果。方法选取2023年2月—2024年2月江苏省靖江市人民医院内分泌科及烧伤整形科收治的70例糖尿病足WagnerⅡ、Ⅲ级溃疡患者为研究对... 目的探究超声清创术+外用重组人粒细胞巨细胞刺激因子凝胶剂在糖尿病足WagnerⅡ、Ⅲ级溃疡治疗中的应用效果。方法选取2023年2月—2024年2月江苏省靖江市人民医院内分泌科及烧伤整形科收治的70例糖尿病足WagnerⅡ、Ⅲ级溃疡患者为研究对象,以随机数表法分为参照组(35例,予以常规清创+胰岛素治疗)和研究组(35例,予以超声清创术+外用重组人粒细胞巨细胞刺激因子凝胶剂治疗)。比较两组溃疡面愈合率、炎症因子水平及治疗总有效率。结果治疗后2周,研究组溃疡创面愈合率略高于参照组,差异有统计学意义(P<0.05);治疗后1、2个月,研究组溃疡创面愈合率明显高于参照组,差异有统计学意义(P均<0.05)。治疗前,两组降钙素原、超敏C反应蛋白水平比较,差异无统计学意义(P均>0.05)。治疗后,两组降钙素原、超敏C反应蛋白水平均降低,且研究组显著低于参照组,差异有统计学意义(P均<0.05)。研究组WagnerⅡ、Ⅲ级溃疡治疗总有效率高于参照组,差异有统计学意义(P<0.05)。结论超声清创术联合外用重组人粒细胞巨细胞刺激因子凝胶剂可促进糖尿病足WagnerⅡ、Ⅲ级溃疡面愈合,控制血清炎症因子水平,整体疗效显著。 展开更多
关键词 尿 Wagner
下载PDF
A pilot study on the combined therapy of granulocyte-macrophage colony-stimulating factor and hepatitis B vaccine on chronic hepatitis B virus carrier children
14
作者 王建设 朱启镕 +1 位作者 张婷 俞蕙 《Chinese Medical Journal》 SCIE CAS CSCD 2002年第12期1824-1828,共5页
Objective To observe the efficacy of treating intrauterine infected chronic hepatitis B virus (HBV) carrier children with a combination of granulocyte macrophage colony stimulating factor (GM CSF) or hepatitis B i... Objective To observe the efficacy of treating intrauterine infected chronic hepatitis B virus (HBV) carrier children with a combination of granulocyte macrophage colony stimulating factor (GM CSF) or hepatitis B immunoglobulin (HBIG) plus recombinant hepatitis B vaccine (rHBvac) Methods A total of 27 chronic HBV infected children, who were born to HBV carrier mothers and received hepatitis B immunoprophylaxis at birth, were randomized into 2 groups: one receiving a combined therapy of 50 μg of GM CSF plus 10 μg of rHBvac injected intramuscularly at the same location (GM CSF group, 14 children) or 200 IU HBIG and 10 μg rHBvac in different muscles (HBIG group, 13 children) on a monthly four dose schedule HBV DNA quantification and other HBV serological markers were tested before and after the four dose therapy Results Twelve children in each group completed the study Of them, 3 children in the GM CSF group and 4 in the HBIG group had elevated serum alanine transaminase (ALT) before the trial, and then 2 in each group became ALT normal after the treatment Before the therapy, hepatitis B e antigen (HBeAg) positivity was found in nine children in the GM CSF group and 10 in the HBIG group One from each group had an HBeAg/anti HBe seroconversion after the treatment The quantity of HBV DNA was significantly lower after the treatment ( P =0 023) in GM CSF group, but was not significantly reduced in HBIG group No subjects were found to be negative for hepatitis B surface antigen (HBsAg) after the treatment, and no serious adverse events occurred in either group Conclusion Combined GM CSF and rHBvac therapy inhibit HBV replication in carrier children who were not protected after treatment with immunoprophylaxis 展开更多
关键词 recombinant hepatitis B vaccine ·granulocyte macrophage colony stimulating factor · chronic hepatitis B
原文传递
生血方联合常规治疗ⅡB-Ⅲ B期宫颈癌同步放化疗骨髓抑制随机平行对照研究 被引量:3
15
作者 刘军 梁惠 岳玉仁 《实用中医内科杂志》 2015年第9期101-103,共3页
[目的]观察生血方联合常规治疗ⅡB-ⅢB期宫颈癌同步放化疗骨髓抑制疗效。[方法]使用随机平行对照方法,将49例住院患者按抽签法简单随机分为两组。对照组23例同步放化疗第1d起口服利可君20mg/次,3次/d;复发阿胶浆20m L/次,3次/d;外照射... [目的]观察生血方联合常规治疗ⅡB-ⅢB期宫颈癌同步放化疗骨髓抑制疗效。[方法]使用随机平行对照方法,将49例住院患者按抽签法简单随机分为两组。对照组23例同步放化疗第1d起口服利可君20mg/次,3次/d;复发阿胶浆20m L/次,3次/d;外照射瓦里安-23EX加速器,6MV-X线根治性调强放疗,DT 50Gy/25fx,5fx/w;腔内放疗Ir192,DT24Gy/4fx,1fx/w;化疗单药顺铂50mg/w×5w方案;常规治疗:同步放化疗期间白细胞(WBC)<3.0×109/L,重组人粒细胞集落刺激因子(300ug/支)300ug皮下注射,1次/d,至WBC>4.0×109/L。血小板(BPC)<50×109/L,白介素-11(1.5mg/支)1.5mg皮下注射,1次/d,至BPC>80×109/L;若血红蛋白(HGB)<60g/L,输红细胞悬液至HGB>70g/L。治疗组26例生血方(生黄芪30g,白术炒12g,茯苓15g,山药30g,菟丝子15g,枸杞子、女贞子各15g、鸡血藤30g),1剂/d,2次/d;同步放化疗方案及常规治疗同对照组。连续治疗40d为1疗程。观测血常规(WBC、HGB、BPC)、不良反应。治疗1疗程,判定疗效。[结果]两组血常规指标均下降(P<0.05),治疗组在白细胞及血小板方面优于对照组(P<0.05)。[结论]生血方联合常规治疗ⅡB-ⅢB期宫颈癌同步放化疗骨髓抑制,疗效满意,无严重不良反应,值得推广。 展开更多
关键词 B-B -11 WBC HGB BPC 西
下载PDF
聚乙二醇化重组人粒细胞刺激因子预防急性淋巴细胞白血病患儿化疗后中性粒细胞减少的临床疗效观察
16
作者 尹凤 邱云 +2 位作者 李龙燕 谢帅 胡红梅 《临床和实验医学杂志》 2024年第4期366-369,共4页
目的探讨聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)预防急性淋巴细胞白血病(ALL)患儿化疗后中性粒细胞减少的临床疗效。方法回顾性分析2020年7月至2023年7月在绵阳市中心医院就诊的60例急性ALL患儿的临床资料。根据治疗方法不同将... 目的探讨聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)预防急性淋巴细胞白血病(ALL)患儿化疗后中性粒细胞减少的临床疗效。方法回顾性分析2020年7月至2023年7月在绵阳市中心医院就诊的60例急性ALL患儿的临床资料。根据治疗方法不同将患儿分为观察组和对照组,各30例。对照组采用重组人粒细胞刺激因子(rhG-CSF)进行干预,观察组采用PEG-rhG-CSF进行干预。比较两组患儿化疗前及化疗3周后绝对中性粒细胞计数(ANC)和白细胞计数(WBC)水平,化疗后3周的中性粒细胞减少的开始时间、持续时间和结束时间,比较两组患儿化疗3周后在白细胞降低发生率、中性粒细胞减少症(FN)发生率及不良反应发生率。结果化疗3周后,两组患者的ANC、WBC水平均较化疗前升高,且观察组患儿的ANC、WBC水平分别为(6.77±4.22)×10^(9)/L、(9.17±3.36)×10^(9)/L,均明显高于对照组[(6.34±2.34)×10^(9)/L、(8.91±3.56)×10^(9)/L],差异均有统计学意义(P<0.05)。两组患儿中性粒细胞减少的开始时间比较,差异无统计学意义(P>0.05);观察组患儿中性粒细胞减少的持续时间和结束时间分别为(8.99±3.31)、(4.79±1.18)d,均明显短于对照组[(15.56±4.91)、(6.97±3.32)d],差异均有统计学意义(P<0.05)。观察组患儿白细胞降低率、FN实际发生率、再住院率和抗生素使用率分别为30.00%、10.00%、3.33%、3.33%,均明显低于对照组(56.67%、40.00%、43.33%、36.67%),差异均有统计学意义(P<0.05)。观察组患儿的ANC减少、感染、骨骼肌肉酸痛、腹泻、恶心呕吐发生率分别为16.67%、6.67%、3.33%、6.67%、10.00%,均明显低于对照组(43.33%、30.00%、16.67%、26.67%、36.67%),差异均有统计学意义(P<0.05)。结论PEG-rhG-CSF能明显缩短急性ALL患儿化疗后中性粒细胞减少的持续时间和结束时间,且不良反应发生率低,在预防急性ALL患儿化疗后中性粒细胞减少方面疗效显著,安全性较高。 展开更多
关键词
下载PDF
Methylation status of c-fms oncogene in HCC and its relationship with clinical pathology 被引量:16
17
作者 Jun Cui Dong Hua Yang +1 位作者 Xiang Jun Bi Zi Rong Fan Department of Gastroenterology, Zhujiang Hospital, The First Military Medical University, Guangzhou 510282, Guangdong Province, China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第1期136-139,共4页
INTRODUCTIONThe mechanism that DNA hypomethylation leads toactivation of oncogene and occurrence of malignantneoplasm is being increasingly recognized byresearchers. Normal DNA methylation playsimportant role in stabi... INTRODUCTIONThe mechanism that DNA hypomethylation leads toactivation of oncogene and occurrence of malignantneoplasm is being increasingly recognized byresearchers. Normal DNA methylation playsimportant role in stabilizing the phenotype of cell.DNA methylation status reduction and/or patternalteration are related to activation and abnormallyhigh expression of some oncogenes and cellularmalignancy[1-6]. c-fms oncogene encodes for colonystimulating factor 1 receptor (CSF-1R)[7], c-fms/CSF-1R was highly expressed in hepatocellularcarcinoma (HCC) tissue, but the mechanismremained obscure[8,9]. 展开更多
关键词 Adult Aged Blotting Southern Carcinoma Hepatocellular DNA Methylation Female Gene Expression Regulation Neoplastic humans Liver Liver Neoplasms Male Middle Aged Phenotype Receptor macrophage colony-stimulating factor Research Support Non-U.S. Gov't
下载PDF
rhG-CSF在治疗儿童化疗性口腔黏膜炎中的应用研究
18
作者 胡云 聂丹 熊磊 《中国现代医生》 2024年第11期82-85,共4页
目的探究重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulating factor,rhG-CSF)在治疗儿童化疗性口腔黏膜炎中的应用效果。方法选取2020年1月至2022年6月于笔者医院肿瘤外科化疗的60例化疗性口腔黏膜炎患儿,按... 目的探究重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulating factor,rhG-CSF)在治疗儿童化疗性口腔黏膜炎中的应用效果。方法选取2020年1月至2022年6月于笔者医院肿瘤外科化疗的60例化疗性口腔黏膜炎患儿,按随机数字表法分为两组,每组30例。对照组采取生理盐水口腔护理,实验组采取rhG-CSF口腔护理。比较两组患儿干预效果、口腔黏膜炎分度、生存质量[健康状况调查简表(36-item short—form,SF-36)]、患儿家长护理满意度。结果实验组总有效率较对照组高,差异有统计学意义(P<0.05)。干预5d,实验组患儿口腔黏膜炎分度结果优于对照组,差异有统计学意义(P<0.05)。干预5d,两组患儿SF-36评分较干预前高,实验组较对照组高,差异有统计学意义(P<0.05)。实验组患儿家长满意度较对照组高,差异有统计学意义(P<0.05)。结论rhG-CSF口腔护理可有效提高儿童化疗性口腔黏膜炎的干预效果,减轻口腔黏膜炎分度,改善患儿生存质量,提高患儿家长护理满意度。 展开更多
关键词
下载PDF
Granulocyte Colony-stimulating Factor-primed Bone Marrow: An Excellent Stem-cell Source for Transplantation in Acute Myelocytic Leukemia and Chronic Myelocytic Leukemia 被引量:1
19
作者 Yuhang Li Min Jiang +8 位作者 Chen Xu Jianlin Chen Botao Li Jun Wang Jiangwei Hu Hongmei Ning Hu Chen Shuiping Chen Liangding Hu 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第1期20-24,共5页
Background:Steady-state bone marrow (SS-BM) and granulocyte colony-stimulating growth factor-primed BM/peripheral blood stem-cell (G-BM/G-PBSC) are the main stem-cell sources used in allogeneic hematopoietic stem... Background:Steady-state bone marrow (SS-BM) and granulocyte colony-stimulating growth factor-primed BM/peripheral blood stem-cell (G-BM/G-PBSC) are the main stem-cell sources used in allogeneic hematopoietic stem-cell transplantation.Here,we evaluated the treatment effects of SS-BM and G-BM/G-PBSC in human leucocyte antigen (HLA)-identical sibling transplantation.Methods:A total of 226 patients (acute myelogenous leukemia-complete remission 1,chronic myelogenous leukemia-chronic phase 1) received SS-BM,G-BM,or G-PBSC from an HLA-identical sibling.Clinical outcomes (graft-versus-host disease [GVHD],overall survival,transplant-related mortality [TRM],and leukemia-free survival [LFS]) were analyzed.Results:When compared to SS-BM,G-BM gave faster recovery time to neutrophil or platelet (P 〈 0.05).Incidence of grade Ⅲ-Ⅳ acute GVHD and extensive chronic GVHD (cGVHD) was lower than seen with SS-BM (P 〈 0.05) and similar to G-PBSC.Although the incidence of cGVHD in the G-BM group was similar to SS-BM,both were lower than G-PBSC (P 〈 0.05).G-BM and G-PBSC exhibited similar survival,LFS,and TRM,but were significantly different from SS-BM (P 〈 0.05).There were no significant differences in leukemia relapse rates among the groups (P 〉 0.05).Conclusions:G-CSF-primed bone marrow shared the advantages of G-PBSC and SS-BM.We conclude that G-BM is an excellent stem-cell source that may be preferable to G-PBSC or SS-BM in patients receiving HLA-identical sibling hematopoietic stem-cell transplantation. 展开更多
关键词 Bone Marrow granulocyte colony-stimulating Growth factor human Leucocyte Antigen-identical Sibling Hematopoietic Stem-cell Transplantation Peripheral Blood Stem-cells
原文传递
重组人粒细胞集落刺激因子联合阿司匹林对不明原因不孕症患者子宫内膜容受性的影响
20
作者 王振燕 李娅 麻莉 《中国性科学》 2024年第1期102-105,共4页
目的探讨重组人粒细胞集落刺激因子(rhG-CSF)联合阿司匹林对不明原因不孕症患者子宫内膜容受性的影响。方法回顾性分析2020年10月至2022年10月河北燕达医院收治的97例不明原因不孕症患者的临床资料。根据治疗方式分为常规组(n=48,采用... 目的探讨重组人粒细胞集落刺激因子(rhG-CSF)联合阿司匹林对不明原因不孕症患者子宫内膜容受性的影响。方法回顾性分析2020年10月至2022年10月河北燕达医院收治的97例不明原因不孕症患者的临床资料。根据治疗方式分为常规组(n=48,采用阿司匹林治疗)和联合组(n=49,采用rhG-CSF联合阿司匹林治疗)。比较两组治疗前后的子宫内膜厚度、子宫血流灌注指标[子宫动脉阻力指数(RI)、搏动指数(PI)、收缩期流速与舒张期流速比值(S/D)],比较两组的妊娠结局。结果治疗后,联合组子宫内膜厚度大于常规组,差异具有统计学意义(P<0.05)。治疗后,两组RI、PI及S/D值均降低,且联合组低于常规组,差异具有统计学意义(P<0.05)。治疗后,联合组生化妊娠率、临床妊娠率均高于常规组,差异具有统计学意义(P<0.05)。结论rhG-CSF联合阿司匹林治疗不明原因不孕症患者,可提高其的子宫内膜容受性,改善子宫血流灌注,有效提高妊娠率。 展开更多
关键词
下载PDF
上一页 1 2 28 下一页 到第
使用帮助 返回顶部